Organovo Holdings, Inc.
http://www.organovo.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Organovo Holdings, Inc.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Market Intel: 3D Bioprinting Forges Ahead With Mini Human Heart, Human Tissue
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.
Execs On The Move, June 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
- Biotechnology
- Research, Analytical Equipment & Supplies
-
Medical Devices
- Biomaterials
- Other Names / Subsidiaries
-
- Opal Merger Sub, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice